Biogen Stock Slides on Q3 Beat as Guidance Cut Shocks Investors
Biogen shares fell about 2.6% after hours Oct. 30 following Q3 results that beat estimates, with revenue at $2.53 billion and adjusted EPS of $4.81. The company cut 2025 non-GAAP EPS guidance to $14.50–$15.00, citing a $1.25 per-share R&D charge. Leqembi sales reached $121 million, up 80% year-over-year. Biogen licensed Vanqua Bio’s inflammation drug for up to $1.06 billion.